International journal of stroke : official journal of the International Stroke Society · 2025
Effect of history of hypertension on efficacy of clopidogrel-aspirin in ischemic stroke.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Dandan, Yan Hongyi, Gao Ying, Chen Weiqi, Johnston S Claiborne, Amarenco Pierre, Bath Philip M, Wang Xuan, Wang Mengxing, Wang Tingting, Yang Yingying, Jing Jing, Wang Chunjuan, Wang Yongjun, Pan Yuesong, Wang Yilong
Аннотация
BACKGROUND: Patients with different hypertension status could potentially respond differently to the treatment of clopidogrel-aspirin owing to thrombosis, antiplatelet resistance, and platelet reactivity.
AIMS: The aim of the study is to examine the efficacy and safety of clopidogrel-aspirin in patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) according to different hypertension status.
METHODS: In the Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial, patients were randomized to either clopidogrel-aspirin or aspirin group. The primary outcome was any new ischemic or hemorrhagic stroke within 90 days. Hypertension status was classified into two categories based on medical history: patients with or without hypertension.
RESULTS: Among 6100 patients with complete data of hypertension status, 3915 (64.2%) were men. Clopidogrel-aspirin compared with aspirin was associated with reduced incidence of new stroke in patients without hypertension (hazard ratio (HR): 0.62, 95% confidence interval (CI): 0.44-0.86, p = 0.004), but not in patients with hypertension (HR: 0.87, 95% CI: 0.71-1.07, p = 0.18; p = 0.085 for interaction).
CONCLUSIONS: In this study, patients without hypertension may have more benefit from receiving treatment with clopidogrel-aspirin than those with hypertension. This finding can be used as an enrichment strategy in the future secondary stroke prevention randomized clinical trials of dual antiplatelet therapy.
TRIAL REGISTRATION: The INSPIRES trial was registered at http://www.
CLINICALTRIALS: gov (unique identifier: NCT03635749).
AIMS: The aim of the study is to examine the efficacy and safety of clopidogrel-aspirin in patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) according to different hypertension status.
METHODS: In the Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial, patients were randomized to either clopidogrel-aspirin or aspirin group. The primary outcome was any new ischemic or hemorrhagic stroke within 90 days. Hypertension status was classified into two categories based on medical history: patients with or without hypertension.
RESULTS: Among 6100 patients with complete data of hypertension status, 3915 (64.2%) were men. Clopidogrel-aspirin compared with aspirin was associated with reduced incidence of new stroke in patients without hypertension (hazard ratio (HR): 0.62, 95% confidence interval (CI): 0.44-0.86, p = 0.004), but not in patients with hypertension (HR: 0.87, 95% CI: 0.71-1.07, p = 0.18; p = 0.085 for interaction).
CONCLUSIONS: In this study, patients without hypertension may have more benefit from receiving treatment with clopidogrel-aspirin than those with hypertension. This finding can be used as an enrichment strategy in the future secondary stroke prevention randomized clinical trials of dual antiplatelet therapy.
TRIAL REGISTRATION: The INSPIRES trial was registered at http://www.
CLINICALTRIALS: gov (unique identifier: NCT03635749).